2026-06-02T18:22:22Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/228052024-11-28T17:28:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16962col_20.500.12105_16967col_20.500.12105_16983col_20.500.12105_16984

00925njm 22002777a 4500 dc Bellet, Meritxell author Ahmad, Faten author Villanueva, Rafael author Valdivia, Carolina author Palomino-Doza, Julian author Ruiz, Ada author Gonzalez, Xavier author Adrover, Encarna author Azaro, Analia author Valls-Margarit, Maria author Parra, Josep Lluis author Aguilar, Juan author Vidal, Maria author Martin, Anastasi author Gavila, Joaquin author Escriva-de-Romani, Santiago author Perello Martorell, Antonia author Hernando, Cristina author Lahuerta, Ainhara author Zamora, Pilar author Reyes, Victoria author Alcalde, Maria author Masanas, Helena author Celiz, Pamela author Ruiz, Isabel author Gil, Miguel author Segui, Miguel Angel author de la Pena, Lorena author 2019-05 Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed. Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019 May;11:1-43. 10.1177/1758835919833867 1758-8359 1758-8340 Therapeutic Advances in Medical Oncology http://hdl.handle.net/20.500.13003/9993 31205497 L627801054 2-s2.0-85066835008 https://hdl.handle.net/20.500.12105/22805 478583000001 CDK inhibitors Palbociclib Ribociclib Breast cancer Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication